Fosun Pharma: Approval for Clinical Trial of Small Molecule Innovator Drug for the Treatment of Advanced Solid Tumors
[March 18, 2021 in Shanghai, China] Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH; 02196.HK) announced that its subsidiary YaoPharma Co., Ltd. ("YaoPharma") had recently received the approval from the NMPA regarding the clinical trial for the YP01001 capsules (the “Investigational New Drug”) for the treatment of advanced solid tumors.
As of February 2021, Fosun Pharma has invested about RMB 33.66 million (unaudited) in the R&D of the Investigational New Drug at this stage.
Driven by innovation and R&D, Fosun Pharma continuously improves its drug R&D system based on the combination of generic and innovator drugs and builds international R&D platforms for small molecule innovator drugs, high-cost generic drugs, biologics and new technology-based therapies, etc.
In the future, the Company will continue to focus on clinical demands, increase its investment in R&D and improve innovation efficiency, so as to bring high-quality and affordable innovator drugs to patients.
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a leading pharmaceutical and healthcare industry group in China. With an eye to the global world, Fosun Pharma operates its businesses in China, with pharmaceuticals and R&D as the core, covering medical devices and medical diagnosis, medical services, pharmaceutical distribution and retail.
Driven by innovation and R&D, Fosun Pharma continuously improves its drug R&D system based on the combination of generic and innovator drugs and builds international R&D platforms for small molecule innovator drugs, high-cost generic drugs, biologics and cell therapies, etc.
In the future, under the guidance of the "4IN" (Innovation, Internationalization, Integration, and Intelligentization) strategy, Fosun Pharma strives to be a leading enterprise in the global pharmaceutical and healthcare markets by adhering to its concept of "Innovation for Good Health".
For more information, please visit our official website：haojimala.com。
The Investigational New Drug is an innovative small molecule chemical drug intended for the treatment of advanced solid tumors (including, among others, liver cancer and gastric cancer). YaoPharma plans to conduct Phase I clinical trial for the Investigational New Drug in China (excluding Hong Kong, Macao and Taiwan) recently after the conditions are available.
As of February 2021, Fosun Pharma has invested about RMB 33.66 million (unaudited) in the R&D of the Investigational New Drug at this stage.
Driven by innovation and R&D, Fosun Pharma continuously improves its drug R&D system based on the combination of generic and innovator drugs and builds international R&D platforms for small molecule innovator drugs, high-cost generic drugs, biologics and new technology-based therapies, etc.
In the future, the Company will continue to focus on clinical demands, increase its investment in R&D and improve innovation efficiency, so as to bring high-quality and affordable innovator drugs to patients.
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a leading pharmaceutical and healthcare industry group in China. With an eye to the global world, Fosun Pharma operates its businesses in China, with pharmaceuticals and R&D as the core, covering medical devices and medical diagnosis, medical services, pharmaceutical distribution and retail.
Driven by innovation and R&D, Fosun Pharma continuously improves its drug R&D system based on the combination of generic and innovator drugs and builds international R&D platforms for small molecule innovator drugs, high-cost generic drugs, biologics and cell therapies, etc.
In the future, under the guidance of the "4IN" (Innovation, Internationalization, Integration, and Intelligentization) strategy, Fosun Pharma strives to be a leading enterprise in the global pharmaceutical and healthcare markets by adhering to its concept of "Innovation for Good Health".
For more information, please visit our official website：haojimala.com。